

Contents

Preface	xiv
Acknowledgments	xv
About the companion website	xvi
Introduction	1
Part 1: Constitutional Analyses	5
Section 1: Chromosome Analysis	7
1 Components of a standard cytogenetics report, normal results and culture failures	9
1.1 Components of a standard cytogenetics report	9
1.2 Prenatal normal results	17
1.3 Neonatal normal results	22
1.4 Normal variants in the population	23
1.5 Disclaimers and recommendations	29
1.6 Culture failures	30
1.7 Contamination	32
2 Mosaicism	35
2.1 Normal results with 30–50 cells examined	37
2.2 Normal and abnormal cell lines	37
2.3 Two or more abnormal cell lines	39
3 Autosomal trisomies – prenatal and livebirths	41
3.1 Introduction	41
3.2 Trisomy 21 – Down syndrome	42
3.3 Mosaic trisomy 21 – mosaic Down syndrome	43
3.4 Trisomy 13 – Patau syndrome	44
3.5 Trisomy 18 – Edwards syndrome	45
3.6 Trisomy 8 – mosaic	46
3.7 Trisomy 9 – mosaic	47
3.8 Trisomy 20 – mosaic, prenatal	47
3.9 Trisomy 22 – mosaic, prenatal	48
4 Translocations	51
4.1 Reciprocal (balanced) translocations	51
4.2 Robertsonian translocations	58

5 Inversions and recombinant chromosomes	67
5.1 Risks of spontaneous abortions and liveborn abnormal offspring	67
5.2 Pericentric inversions and their recombinants	67
5.3 Paracentric inversions and their recombinants	71
6 Visible deletions, duplications and insertions	75
6.1 Definitions	75
6.2 Visible duplications	79
6.3 Balanced insertions	80
7 Unidentifiable marker chromosomes, derivative chromosomes, chromosomes with additional material and rings	85
7.1 Marker chromosomes	85
7.2 Derivative chromosomes	87
7.3 Chromosomes with additional material	90
7.4 Ring chromosomes	91
7.5 Homogenously staining regions	94
8 Isochromosomes, dicentric chromosomes and pseudodicentric chromosomes	97
8.1 Isochromosomes/dicentric chromosomes	97
8.2 Pseudodicentric chromosomes	104
9 Composite karyotypes and other complex rearrangements	107
9.1 Composite karyotypes	107
9.2 Complex rearrangements	109
10 Sex chromosome abnormalities	115
10.1 X chromosome aneuploidies – female phenotypes	115
10.2 X and Y chromosome aneuploidies – male phenotypes	120
10.3 X chromosome structural abnormalities	122
10.4 Y chromosome structural abnormalities	128
10.5 46,XX males and 46,XY females	132
10.6 X chromosome translocations	135
11 Fetal demises/spontaneous abortions	143
11.1 Aneuploid rate	143
11.2 Confined placental mosaicism	144
11.3 Hydatidiform moles	145
11.4 Monosomy X in a fetus	146
11.5 Trisomies in a fetus	146
11.6 Double trisomy	149
11.7 Triploidy	150
11.8 Tetraploidy	151
12 Uniparental disomy	155
12.1 Uniparental disomy of chromosome 14	157
12.2 Uniparental disomy of chromosome 15	158
12.3 Uniparental disomy of chromosome 11p15	159

Section 2: Fluorescence <i>In Situ</i> Hybridization (FISH) Analysis	161
13 Metaphase analysis	163
13.1 Introduction	163
13.2 Reporting normal results	164
13.3 Common disclaimers	166
13.4 Microdeletions	167
13.5 Microduplications	190
13.6 Fluorescence <i>in situ</i> hybridization for chromosome identification	198
13.7 Subtelomere fluorescence <i>in situ</i> hybridization analysis	200
14 Interphase analysis	205
14.1 Introduction	205
14.2 Example report of interphase analysis	206
14.3 Common disclaimers	207
14.4 Reporting normal results	208
14.5 Abnormal prenatal/neonatal results	211
14.6 Abnormal product of conception FISH abnormalities	218
14.7 Molar pregnancies	222
14.8 Preimplantation genetic diagnosis	222
15 Integrated chromosome and FISH analyses	231
15.1 ISCN rules and reporting normal results by chromosomes and FISH	232
15.2 ISCN rules and reporting abnormal chromosomes and FISH	233
15.3 ISCN rules and reporting of chromosomes and subtelomere FISH	237
Section 3: Chromosomal Microarray Analysis (CMA)	243
16 Bacterial artificial chromosome, oligoarray and single nucleotide polymorphism array methodologies for analysis	245
16.1 Introduction	245
16.2 Clinical utility of chromosomal microarray analysis	250
16.3 Guidelines for classification states	251
16.4 ISCN rules and reporting of normal results	252
16.5 Comments, disclaimers and recommendations	253
17 Microarray abnormal results	257
17.1 Reporting of abnormal results	257
17.2 Loss or gain of a single chromosome	258
17.3 Loss or gain of a whole chromosome complement	262
17.4 Microdeletions	263
17.5 Microduplications	265
17.6 Derivative chromosomes	267
17.7 Variants of unknown significance	269
17.8 Uniparental disomy/loss of heterozygosity/regions of homozygosity	269

17.9	Mosaicism	271
17.10	Common comments in abnormal reports	273
17.11	Microarrays with concurrent FISH studies and/or chromosome studies	274
17.12	Microarrays with concurrent parental studies	274
17.13	Preimplantation genetic diagnosis testing	275
17.14	Non-invasive prenatal testing	276
18	Pathogenic chromosomal microarray copy number changes by chromosome order	285
18.1	Chromosome 1	285
18.2	Chromosome 2	287
18.3	Chromosome 3	289
18.4	Chromosome 4	290
18.5	Chromosome 5	291
18.6	Chromosome 7	292
18.7	Chromosome 8	293
18.8	Chromosome 14	294
18.9	Chromosome 15	294
18.10	Chromosome 16	296
18.11	Chromosome 17	298
18.12	Chromosome 19	301
18.13	Chromosome 22	302
18.14	Chromosome X	306
19	Integrated reports with cytogenetics, FISH and microarrays	315
19.1	Reporting of a deletion	315
19.2	Reporting of a supernumerary chromosome	316
19.3	Reporting of an unbalanced translocation – deletion/duplication	318
19.4	Reporting of multiple abnormal cell lines	322
Part 2: Acquired Abnormalities in Hematological and Tumor Malignancies		325
Section 1: Chromosome Analysis		327
20	Introduction	329
20.1	Description of World Health Organization classification for hematological malignancies	332
20.2	Description of different tumor types with significant cytogenetic abnormalities	332
20.3	Set-up and analysis of specific cultures for optimal results	333
20.4	Nomenclature rules for normal and simple abnormal results	336
20.5	Common report comments for hematological malignancies	338
21	Results with constitutional or other non-neoplastic abnormalities	347
21.1	Possible constitutional abnormalities observed	347
21.2	Age-related abnormalities	349
21.3	Non-clonal aberrations	351
21.4	No growth and poor growth	354

22 Cytogenetic abnormalities in myeloid disorders	357
22.1 Introduction to myeloid disorders	357
22.2 Individual myeloid abnormalities by chromosome order	360
23 Cytogenetic abnormalities in lymphoid disorders	395
23.1 Introduction to lymphoid disorders	395
23.2 Hyperdiploidy and hypodiploidy	396
23.3 Individual lymphoid abnormalities by chromosome order	398
24 Common biphenotypic abnormalities and secondary changes	423
24.1 Translocation (4;11)(q21;q23)	423
24.2 Del(9q)	424
24.3 Translocation (11;19)(q23;p13.3)	424
24.4 Del(12)(p11.2p13)	425
24.5 Trisomy 15	425
24.6 i(17q)	426
25 Reporting complex abnormalities and multiple cell lines	429
25.1 Stemline and sideline abnormalities	430
25.2 Unrelated abnormal clones	434
25.3 Composite karyotypes	435
25.4 Double minute chromosomes	436
25.5 Modal ploidy numbers	438
25.6 Multiple abnormal cell lines indicative of clonal evolution	440
26 Breakage disorders	445
26.1 Ataxia telangiectasia	445
26.2 Bloom syndrome	446
26.3 Fanconi anemia	447
26.4 Nijmegen syndrome	448
27 Cytogenetic abnormalities in solid tumors	451
27.1 Clear cell sarcoma	451
27.2 Chondrosarcoma	452
27.3 Ewing sarcoma	453
27.4 Liposarcoma	453
27.5 Neuroblastoma	454
27.6 Rhabdomyosarcoma	455
27.7 Synovial sarcoma	456
27.8 Wilms tumor	456
Section 2: Fluorescence <i>In Situ</i> Hybridization (FISH) Analysis	459
28 Introduction to FISH analysis for hematological disorders and solid tumors	461
28.1 General results	462
28.2 Bone marrow transplantation results	468

29 Recurrent FISH abnormalities in myeloid disorders	471
29.1 Individual abnormalities in myeloid disorders by chromosome order	471
29.2 Biphentotypic and therapy-related abnormalities	491
29.3 Panels of probes	492
30 Recurrent FISH abnormalities in lymphoid disorders	499
30.1 Individual abnormalities in lymphoid disorders by chromosome order	499
30.2 Panels of probes	520
31 Integrated reports with cytogenetics and FISH in hematological malignancies	531
31.1 Translocation (9;22) with BCR/ABL1 FISH analysis	531
31.2 Monosomy 7 with a marker chromosome and chromosome 7 FISH analysis	532
31.3 Complex abnormalities with the MDS FISH panel	532
31.4 Complex abnormalities with ALL FISH panel	533
31.5 Complex abnormalities with MM FISH panel	535
31.6 Complex abnormalities with AML FISH panel	536
31.7 Complex abnormalities with AML FISH panel in therapy-related disease	537
32 Recurrent FISH abnormalities in solid tumors using paraffin-embedded tissue	541
32.1 Ewing sarcoma	544
32.2 Liposarcoma	545
32.3 Neuroblastoma	546
32.4 Non-small cell lung cancer	547
32.5 Oligodendroglioma	552
32.6 Rhabdomyosarcoma	554
32.7 Synovial sarcoma	554
33 Breast cancer – HER2 FISH analysis	559
33.1 Common report comments	560
33.2 Example HER2 reports	561
33.3 Genetic heterogeneity	563
34 Bladder cancer FISH analysis	569
34.1 Common report comments	570
34.2 Example reports	570
Section 3: Chromosomal Microarray Analysis (CMA)	577
35 Chromosomal microarray analysis for hematological disorders	579
35.1 Introduction	579
35.2 Categories of abnormalities	580
35.3 Complex abnormalities throughout the genome, chromothripsis and homozygosity	581
35.4 Normal results and disclaimers	582
35.5 Example abnormal results in hematological malignancies	583

36 Chromosomal microarrays for tumors	595
36.1 Introduction and disclaimers	595
36.2 Breast cancer	596
36.3 Lung cancer	604
36.4 Colon cancer	606
36.5 Prostate cancer	607
36.6 Unspecified tumor present	607
37 Integrated reports with chromosomes, FISH and microarrays	611
37.1 Homozygous deletion of 9p21 identified by FISH and CMA	611
37.2 Identifying marker chromosomes by chromosome analysis, FISH and CMA	612
37.3 Unbalanced translocation identification by chromosomes, FISH and CMA	614
Appendix 1: Example assay-specific reagent (ASR) FISH validation plan for constitutional disorders and hematological malignancies on fresh tissue	617
Glossary	623
Index	641